Literature DB >> 8950068

Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals.

B Darpö1, O Almgren, R Bergstrand, S Franzén, N Edvardsson.   

Abstract

The aim of the present study was to assess the frequency dependency of the effects of almokalant, a selective class III antiarrhythmic drug, on ventricular repolarization using recordings of monophasic action potentials and measurements of ventricular paced QT intervals. Twenty male volunteers were studied during almokalant infusion aiming at plasma concentrations (Cpl) of 20, 50, 100, and 150 nmol/l. The duration of monophasic action potential at 90% repolarization (MAPD) was measured during incremental and premature ventricular extrastimulation. The ventricular paced QT interval was measured during incremental stimulation from the apical region (RV APEX) and the outflow tract (RVOT) of the right ventricle, and the frequency dependence was analyzed using a linear regression model. At an almokalant dose of Cpl > or = 50, there was a significant prolongation of the MAPD of 10-15%. The prolongation was of equal magnitude at all paced cycle lengths (CL). The MAPD of ventricular extrasystole increased in parallel over the range of coupling intervals studied and was significantly prolonged at Cpl 100 and 150. The ratio between the MAPD of the extrasystoles and preceding beats was unaltered after almokalant infusion. The ventricular paced QT intervals increased during almokalant infusion in a similar manner as that of the MAPD. During RV APEX stimulation, the prolongation was more pronounced at low heart rates, an effect that was not seen during RV OT stimulation. Almokalant significantly prolonged the MAPD at dose levels Cpl > or = 50. There was no evidence of a frequency dependence of this effect. The ventricular paced QT intervals were prolonged in a similar manner as that of the MAPD, and this effect exhibited a small reverse frequency dependence during RV APEX stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950068     DOI: 10.1007/bf00050994

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  28 in total

1.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.

Authors:  M C Sanguinetti; N K Jurkiewicz
Journal:  J Gen Physiol       Date:  1990-07       Impact factor: 4.086

2.  Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes.

Authors:  E Carmeliet
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

3.  Use-dependent block of the delayed K+ current in rabbit ventricular myocytes.

Authors:  E Carmeliet
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

4.  Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031.

Authors:  C Abrahamsson; G Duker; C Lundberg; L Carlsson
Journal:  Cardiovasc Res       Date:  1993-05       Impact factor: 10.787

5.  Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for "reverse use dependent" block.

Authors:  A Ohler; G J Amos; E Wettwer; U Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

6.  Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation.

Authors:  S B Olsson; N Edvardsson
Journal:  Am Heart J       Date:  1981-11       Impact factor: 4.749

7.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

Authors:  L M Hondeghem; D J Snyders
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

8.  Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia. Almokalant PSVT Study Group.

Authors:  B Darpö; N Edvardsson
Journal:  J Cardiovasc Pharmacol       Date:  1995-08       Impact factor: 3.105

9.  Electrical restitution in the endocardium of the intact human right ventricle.

Authors:  J M Morgan; D Cunningham; E Rowland
Journal:  Br Heart J       Date:  1992-01

10.  Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans.

Authors:  K Nademanee; W G Stevenson; J N Weiss; V B Frame; M G Antimisiaris; T Suithichaiyakul; C M Pruitt
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

View more
  2 in total

1.  Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies.

Authors:  Nkechi E Azie; Gregory Adams; Borje Darpo; Steven F Francom; Emery C Polasek; Joy M Wisser; Joseph C Fleishaker
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-04       Impact factor: 1.468

2.  Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.

Authors:  Nenad Sarapa; Joel Morganroth; Jean-Philippe Couderc; Steven F Francom; Borje Darpo; Joseph C Fleishaker; Janet D McEnroe; William T Chen; Wojciech Zareba; Arthur J Moss
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.